OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

• ClinicalTrials.gov Identifier: NCT03747458
• Recruitment Status: Recruiting
• First Posted: November 20, 2018
• Last Update Posted: March 23, 2023
• Sponsor: Optinose US Inc.
• Information provided by (Responsible Party): Optinose US Inc.

Study Description

Brief Summary:

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

Condition or disease	Intervention/treatment	Phase
Bilateral Nasal Polyposis	Drug: OPN-375	Phase 3

Detailed Description:

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 120 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: 16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase
• Actual Study Start Date: December 31, 2018
• Estimated Primary Completion Date: December 2023
• Estimated Study Completion Date: December 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: OPN-375 186 μg BID; Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks	Drug: OPN-375; OPN-375, BID
Placebo Comparator: Placebo; Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks	Drug: OPN-375; OPN-375, BID

Outcome Measures

Primary Outcome Measures :

1. Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4 [ Time Frame: 4 Weeks ]
   Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.
2. Mean change from baseline at Week 16 in total polyp grade [ Time Frame: 16 Weeks ]
   Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

Secondary Outcome Measures :

1. Change in bilateral polyp grade over time [ Time Frame: 16 Weeks ]
   nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
2. Percentage of subjects with a ≥1 point improvement in polyp grade [ Time Frame: 16 Weeks ]
   nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
3. Percentage of subject with a grade of 0 on at least one side of the nose [ Time Frame: 16 Weeks ]
   nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
4. Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores) [ Time Frame: 16 Weeks ]
   The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
5. Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores) [ Time Frame: 16 Weeks ]
   The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
6. Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores) [ Time Frame: 16 Weeks ]
   The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
7. Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores) [ Time Frame: 16 Weeks ]
   Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)
8. The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase [ Time Frame: 16 Weeks ]
   The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
9. Subjects will assess their global impression of change since starting the study drug using the PGIC scale [ Time Frame: 16 Weeks ]
   Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse
10. Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5). [ Time Frame: 16 Weeks ]
    Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).
11. Proportion of subjects eligible for surgical intervention (independent of actual surgery performed) [ Time Frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination) ]

    The assessment criteria are as follows:

    • Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months.
    • Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks.
    • Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks.
    • Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score > 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.

Other Outcome Measures:

1. Assessment of safety from physical examination-measuring weight [ Time Frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination) ]
   Assessment of safety from physical examination-weight measured in kg or lb
2. Assessment of safety from physical examination-measuring height [ Time Frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination) ]
   Assessment of safety from physical examination-height measured in cm or in
3. Assessment of safety by recording the severity of AEs [ Time Frame: 16 Weeks ]
   Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe
4. Assessment of safety by nasal examination [ Time Frame: 16 Weeks ]
   Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma
5. Assessment of safety by ocular examination-visual acuity [ Time Frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination) ]
   Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...
6. Assessment of safety by ocular examination-Intraocular Pressure [ Time Frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination) ]
   Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is >21mmHg
7. Assessment of safety by ocular examination-Cataract Evaluation [ Time Frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination) ]
   Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe
8. Assessment of safety measuring vital signs (blood pressure) [ Time Frame: 16 Weeks ]
   Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)
9. Assessment of safety measuring vital signs (pulse) [ Time Frame: 16 Weeks ]
   measure pulse in beats per minute (bpm)
10. Assessment for safety from the collection of information for concomitant medications usage [ Time Frame: 16 Weeks ]
11. Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL) [ Time Frame: 8 hours, 1 to 2 weeks before randomization ]
    PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-t) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
12. Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL) [ Time Frame: 8 hours, 1 to 2 weeks before randomization ]
    PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-∞) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
13. Assessment of pharmacokinetics - AUCex (%) [ Time Frame: 8 hours, 1 to 2 weeks before randomization ]
    PK Laboratory to determine the concentrations of fluticasone propionate [AUCex (%) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
14. Assessment of pharmacokinetics - Cmax (pg/mL) [ Time Frame: 8 hours, 1 to 2 weeks before randomization ]
    PK Laboratory to determine the concentrations of fluticasone propionate [Cmax (pg/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
15. Assessment of pharmacokinetics - tmax (h) [ Time Frame: 8 hours, 1 to 2 weeks before randomization ]
    PK Laboratory to determine the concentrations of fluticasone propionate [tmax (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
16. Assessment of pharmacokinetics - t1/2 (h) [ Time Frame: 8 hours, 1 to 2 weeks before randomization ]
    PK Laboratory to determine the concentrations of fluticasone propionate [t1/2 (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

Eligibility Criteria

• Ages Eligible for Study: 12 Years to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).

2. Female subjects, if sexually active, must:

   1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
   2. be surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
   3. or agree to abstinence.
3. Ability to read and speak English
4. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (β-hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline)
5. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening)
6. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over the last 7 days of the run-in period (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)
7. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2005 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study. Visit 1 (Screening)
8. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, as well as inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). (Note: intranasal antibiotics and saline are permissible)
9. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to the Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.
10. Subject (with assistance from parent or legal guardian if needed) must demonstrate the ability to correctly complete the daily diary during the run-in period to be eligible for randomization.
11. Must demonstrate correct use of the demo exhalation delivery system (EDS).
12. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an informed consent to participate in the study.

Exclusion Criteria:

1. Pregnancy or lactation
2. Has a history of cystic fibrosis
3. Have used XHANCE® (fluticasone propionate) nasal spray within the past 2 months
4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation
5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation
6. Have history of nasal septum erosion, ulceration or perforation or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy
7. Other significant nasal pathology or abnormal anatomy
8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)
9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime) Visit 1 (Screening)
10. Have had any surgery on the nasal septum
11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)
12. History of any surgical procedure that prevents the ability to accurately to diagnose or grade polyps if the subject requires nasoendoscopy
13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
14. Have significant oral structural abnormalities (e.g., a cleft palate)
15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks
17. Have an allergy, hypersensitivity, or contraindication to corticosteroids or steroids
18. Have an allergy or hypersensitivity to any excipients in study drug
19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma
20. Currently receiving Nucala (mepolizumab), Cinquair (reslizumab), Dupixent (dupilumab), or Omalizumab (Xolair®) (note patients should not be removed from their therapy for the sole purpose of study participation)
21. Have nasal or oral candidiasis
22. Have taken a potent CYP3A4-inhibitor within 14 days before Visit 1 (Screening)
23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation
24. History or current diagnosis of glaucoma or ocular hypertension (intraocular pressure >21 mmHg)
25. History of intraocular pressure elevation on any form of steroid therapy
26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment
27. A recent (within 1 year of Visit 1 (Screening) clinically significant history of drug or alcohol use, abuse, or dependence)
28. Positive urine drug screen at Visit 1 (Screening) for stimulants, opioids, or cocaine
29. Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)
30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator

Contacts and Locations

Contacts

Contact: Amy Berman; 267-521-0524; amy.berman@optinose.com

Contact: Diane Anderson; 267-521-0714; diane.anderson@optinose.com

Locations

United States, Alabama

Clinical Research Center of Alabama; Recruiting

Birmingham, Alabama, United States, 35209

Contact: Beth Hagerty 205-209-4130 bhagerty@alabamaallergy.com

United States, Arizona

Arizona Allergy and Immunology Research; Recruiting

Gilbert, Arizona, United States, 85234

Contact: Marguerite Abrahamson 480-626-6600 mabrahamson@santanallergy.com

San Tan Allergy & Asthma; Recruiting

Gilbert, Arizona, United States, 85234

Contact: Marguerite Abrahamson 480-626-6600 mabrahamson@santanallergy.com

United States, California

Kern Research; Recruiting

Bakersfield, California, United States, 93301

Contact: Kristy Walker 661-864-7710 kern4reserach@aol.com

Central California Clinical Research; Recruiting

Fresno, California, United States, 93720

Contact: Latisha Richardson 559-432-3303 ext 229 lrichardson@ccent.com

Children's Hospital of Orange County; Recruiting

Orange, California, United States, 92868

Contact: Eric Rodriguez 714-509-3344 Eric.Rodriguez@choc.org

Allergy and Asthma Consultants; Recruiting

Redwood City, California, United States, 94063

Contact: Sherry Lipson 650-216-6111 Sherry.lipsonallergy@gmail.com

Sacramento ENT; Recruiting

Roseville, California, United States, 95661

Contact: Rose Khalatyan 916-786-3399 ext 1101 vkhalatyan@sacent.com

United States, Colorado

Children's Hospital Colorado; Recruiting

Aurora, Colorado, United States, 80045

Contact: Jordyn Dinwiddie 702-777-5841 jordyn.dinwiddie@childrenscolorado.org

United States, Connecticut

Yale School of Medicine, Section of Otolaryngology; Recruiting

New Haven, Connecticut, United States, 06519

Contact: Sherrie Bitterman 203-584-8404 sherrie.bitterman@yale.edu

United States, Florida

Nemours Children's Specialty Care; Recruiting

Jacksonville, Florida, United States, 32207

Contact: Linda Wheeler 904-697-3015 linda.wheeler@nemours.org

United States, Georgia

Children's Healthcare of Atlanta; Recruiting

Atlanta, Georgia, United States, 30322

Contact: Eric hoar 404-785-1376 eric.hoar@choa.org

United States, Illinois

Rush University Medical Center - Department of Otorhinolaryngology; Recruiting

Chicago, Illinois, United States, 60612

Contact: Mahendra Shah 312-942-9967 mahendrakumar_shah@rush.edu

Chicago ENT; Recruiting

Chicago, Illinois, United States, 60657

Contact: Joseph Ninos 773-289-1823 njoseph@chicagoent.com

United States, Kentucky

Kentuckiana ENT; Recruiting

Louisville, Kentucky, United States, 40205

Contact: Tracie Bland 502-583-9425 tbland@kentuckianaent.com

United States, Louisiana

Ochsner Medical Center, Otorhinolaryngology Department; Recruiting

New Orleans, Louisiana, United States, 70121

Contact: Nabami Malekera 504-842-6011 carine.malekera@ochsner.org

United States, Minnesota

Children's Minnesota; Recruiting

Minneapolis, Minnesota, United States, 55102

Contact: Hanan Zavala 612-813-7131 hanan.zavala@childrensmn.org

United States, Missouri

University of Missouri Medical Center; Recruiting

Columbia, Missouri, United States, 65212

Contact: Rebecca Schneider 573-882-2549 schneiderri@health.missouri.edu

United States, New York

University of Rochester; Recruiting

Rochester, New York, United States, 14642

Contact: Paul Allen 585-275-1186 paul_allen@urmc.rochester.edu

United States, North Carolina

Allergy Asthma & Immunology Research Institute; Recruiting

Charlotte, North Carolina, United States, 28204

Contact: Alison Mathews 704-910-1402 ext 350 alisonm@aairofcharlotte.com

United States, Oklahoma

Allergy, Asthma & Clinical Research Center; Recruiting

Oklahoma City, Oklahoma, United States, 73120

Contact: Anika Nahar 405-286-9431 anika@mtarpay.com

Vital Prospects Clinical Research Institute, P.C.; Recruiting

Tulsa, Oklahoma, United States, 74136

Contact: Rylee Mendez 918-392-4550 rylee.mendez@aaicenter.net

United States, South Carolina

MUSC Department of Otolaryngology, Head and Neck Surgery; Recruiting

Charleston, South Carolina, United States, 29425

Contact: Shaun Nguyen 843-792-1356 nguyensh@musc.edu

Carolina ENT; Recruiting

Orangeburg, South Carolina, United States, 29118

Contact: Simone Ansley 803-536-5511 sansley700@gmail.com

United States, Texas

STAAMP Research; Recruiting

San Antonio, Texas, United States, 78229

Contact: Carlos Rodriguez 210-451-9911 crc@staampallergy.com

United States, Utah

University of Utah; Recruiting

Salt Lake City, Utah, United States, 84132

Contact: Martin Carricaburu 801-581-3363 martin.carricaburu@hsc.utah.edu

United States, Virginia

Eastern Virginia Medical School - Otolaryngology; Recruiting

Norfolk, Virginia, United States, 23507

Contact: Laura Stone 757-388-6238 stonelj@evms.edu

United States, Washington

Spokane ENT; Recruiting

Spokane Valley, Washington, United States, 99216

Contact: Christi Witte 509-496-2782 Christi@principleresearchsolutions.com

United States, West Virginia

West Virginia University; Recruiting

Morgantown, West Virginia, United States, 26506

Contact: Aimie Jones 304-598-6135 Jonesai@wvumedicine.org

Sponsors and Collaborators

Optinose US Inc.

Investigators

• Study Director: Jennifer Carothers; Optinose US Inc.
• Study Chair: John Messina; Optinose US Inc.

More Information

• Responsible Party: Optinose US Inc.
• ClinicalTrials.gov Identifier: NCT03747458
• Other Study ID Numbers: OPN-FLU-NP-3103
• First Posted: November 20, 2018
• Last Update Posted: March 23, 2023
• Last Verified: March 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Nasal Polyps; Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Polyps; Pathological Conditions, Anatomical